Patents by Inventor Kypros Nicolaides

Kypros Nicolaides has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170156627
    Abstract: Particular aspects of the invention are methods for assaying metabolite levels in samples from a patient during pregnancy using nuclear magnetic resonance and direct flow injection mass spectrometry. In various methods, the assayed metabolites may be acylcarnitine or one or more of C3-OH (hydroxypropionylcarnitine), C5-OH (C3DC), C10, C5:1-DC (glutaconylcarnitine), C14:1-OH (hydroxytetradecenoylcarnitine) and C14:2-OH. One or more methods also may include measuring nuchal translucency of the fetus. Other methods relate to predicting fetal congenital heart defects in a fetus.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 8, 2017
    Applicants: BIOSCREENING AND DIAGNOSTICS LLC, KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST
    Inventors: Ray O. Bahado-Singh, Kypros Nicolaides
  • Publication number: 20160305950
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 20, 2016
    Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
  • Patent number: 9250251
    Abstract: The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: February 2, 2016
    Assignee: WALLAC OY
    Inventors: Kypros Nicolaides, Tarja Ahola
  • Publication number: 20150087553
    Abstract: The present invention is directed to methods for predicting a pregnant woman's risk of developing early-onset preeclampsia or late-onset preeclampsia. The methods are based on measuring one or more metabolites obtained from a pregnant woman's bodily fluid, such as blood or urine, which were found to be predictive of early-onset preeclampsia and late-onset preeclampsia.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 26, 2015
    Inventors: Ray O. Bahado-Singh, Kypros Nicolaides
  • Publication number: 20150080263
    Abstract: The present invention is directed to methods for predicting a pregnant woman's risk of carrying a fetus with Down syndrome (Trisomy 21) or Trisomy 18. The methods are based on measuring one or more metabolites obtained from a pregnant woman's bodily fluid, such as blood or urine, and found to be predictive of Trisomy 21 or Trisomy 18.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 19, 2015
    Inventors: Ray O. Bahado-Singh, Kypros Nicolaides
  • Patent number: 8932823
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: January 13, 2015
    Assignees: Wallac Oy, The Fetal Medicine Foundation
    Inventors: Howard Cuckle, Kypros Nicolaides
  • Publication number: 20140113319
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Application
    Filed: December 31, 2013
    Publication date: April 24, 2014
    Applicants: PerkinElmer Health Sciences, Inc., Fetal Medicine Foundation, The, Wallac Oy
    Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
  • Publication number: 20140113320
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Application
    Filed: December 31, 2013
    Publication date: April 24, 2014
    Applicants: Fetal Medicine Foundation, The, Wallac Oy
    Inventors: Howard Cuckle, Kypros Nicolaides
  • Patent number: 8673582
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: March 18, 2014
    Assignees: Wallac Oy, The Fetal Medicine Foundation
    Inventors: Howard Cuckle, Kypros Nicolaides
  • Patent number: 8647832
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: February 11, 2014
    Assignees: PerkinElmer Health Sciences, Inc., Wallac Oy, The Fetal Medicine Foundation
    Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
  • Publication number: 20130344503
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Application
    Filed: July 18, 2013
    Publication date: December 26, 2013
    Applicants: The Fetal Medicine Foundation, Wallac Oy, PerkinElmer Health Sciences, Inc.
    Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
  • Publication number: 20100304412
    Abstract: The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
    Type: Application
    Filed: January 26, 2009
    Publication date: December 2, 2010
    Inventors: Howard Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
  • Publication number: 20070185200
    Abstract: It has been demonstrated that the level of asymmetric dimethylarginine (ADMA) increases in women that subsequently develop pre-eclampsia or whose fetus subsequently develops intrauterine growth restriction (IUGR) and that ADMA plays a key role in the development of maternal hypertension. Accordingly, the level of ADMA in a pregnant woman can be used to determine whether or not a pregnant woman is at risk of developing pre-eclampsia or whether or not a fetus is at risk of developing IUGR. Furthermore, antagonists of ADMA activity are useful in the inhibition or prevention of pre-eclampsia or inhibition or prevention of IUGR.
    Type: Application
    Filed: April 19, 2004
    Publication date: August 9, 2007
    Applicant: University College London
    Inventors: Makrina Savvidou, Aroon Hingorani, Patrick Vallance, Kypros Nicolaides